Bamco Inc. NY Purchases 274,287 Shares of Establishment Labs Holdings Inc. $ESTA

Bamco Inc. NY boosted its holdings in Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 30.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,181,824 shares of the company’s stock after buying an additional 274,287 shares during the period. Bamco Inc. NY owned approximately 4.07% of Establishment Labs worth $48,443,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. State of Wyoming purchased a new position in shares of Establishment Labs in the third quarter valued at $71,000. Osaic Holdings Inc. grew its holdings in Establishment Labs by 900.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after buying an additional 1,800 shares in the last quarter. Brian Low Financial Group LLC bought a new stake in shares of Establishment Labs during the third quarter valued at about $223,000. Private Advisor Group LLC lifted its holdings in shares of Establishment Labs by 14.1% in the third quarter. Private Advisor Group LLC now owns 5,450 shares of the company’s stock worth $223,000 after buying an additional 675 shares in the last quarter. Finally, Patriot Financial Group Insurance Agency LLC boosted its position in shares of Establishment Labs by 5.8% in the third quarter. Patriot Financial Group Insurance Agency LLC now owns 6,375 shares of the company’s stock valued at $261,000 after acquiring an additional 350 shares during the period. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on ESTA shares. Wall Street Zen raised shares of Establishment Labs from a “hold” rating to a “buy” rating in a report on Saturday, March 7th. JPMorgan Chase & Co. upped their price target on shares of Establishment Labs from $71.00 to $80.00 and gave the stock an “overweight” rating in a report on Wednesday, December 17th. Citigroup reduced their target price on Establishment Labs from $81.00 to $74.00 and set a “neutral” rating for the company in a research report on Wednesday, March 11th. Needham & Company LLC raised their price target on Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a report on Tuesday, February 24th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a report on Monday, December 29th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Establishment Labs currently has an average rating of “Moderate Buy” and an average price target of $86.86.

Establishment Labs Stock Down 0.4%

ESTA opened at $63.35 on Monday. The company has a quick ratio of 2.00, a current ratio of 3.04 and a debt-to-equity ratio of 10.51. The business’s fifty day simple moving average is $70.25 and its 200 day simple moving average is $60.67. Establishment Labs Holdings Inc. has a 52 week low of $26.56 and a 52 week high of $83.31. The stock has a market cap of $1.86 billion, a PE ratio of -36.41 and a beta of 0.91.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings data on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.13. The firm had revenue of $64.62 million during the quarter, compared to analysts’ expectations of $63.80 million. Establishment Labs had a negative return on equity of 201.79% and a negative net margin of 24.19%.The company’s revenue for the quarter was up 45.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($1.19) EPS. As a group, research analysts expect that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current fiscal year.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.